Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on VOLITIONRX LTD. We currently have 6 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Triage test ready for launch
06 Jan 17
VolitionRx reported in January 2017 that it had received a CE mark for its Nu.Q™ triage test for colorectal cancer (CRC). The company is targeting commercialization of the test initially in EU member states that have established fecal immunochemical testing (FIT) programs (of which there are 14 in total), and the CE mark should enable launches in these territories as early as 2017.
First product ready to enter market
23 Sep 16
VolitionRx is a developer of blood-based diagnostics for cancer that detect the quantity and composition of cell-free nucleosomes (a complex of protein and DNA) present in the blood. The company announced its first commercial product, the NuQ triage colorectal cancer test, will launch in select European countries in early 2017. The product is not a diagnostic test, but is designed to reduce the number of colonoscopies by screening false positives from fecal immunochemical tests (FIT).
Closing in on commercialization
01 Apr 16
VolitionRx announced a new commercialization strategy for the US with its FY15 results. The company will seek a 510(k) approval in the US as an intermediate step to eventual PMA approval. This will allow for a quicker commercial launch of the NuQ colorectal test in the US, but would limit its marketing to “informing” a physician’s diagnosis instead of being a definitive diagnostic tool. The nearest-term revenues are in Europe, where a CE-mark approval and commercial launch are slated for late 2016.
New results boost NuQ for lung and CRC
07 Jan 16
VolitionRx recently released data for NuQ in colorectal and lung cancer, which both exceeded results from previous trials. In colorectal cancer (CRC), the test when adjusted for age detected 91% of tumors with 90% specificity in its first completed prospective study, unlike previous retrospective studies. The company also released encouraging interim lung cancer data detecting 93% of tumors with 91% specificity using the NuQ test in combination with smoking history, which positions the test as one of the most accurate non-invasive lung cancer diagnostics.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
11 Jan 17
Joules Group (JOU): Strong festive trading (BUY) | Shoe Zone (SHOE): Tough FY16 could be just the beginning (HOLD) | H&T (HAT): Alternative lender emerging (BUY) | Omega Diagnostics* (ODX): ISO accreditation received for Pune, India (CORP) | Redcentric* (RCN): Interims – restoring forecasts (CORP)
N+1 Singer - Morning Song 11-01-2017
11 Jan 17
Xaar has signed an agreement with Xerox Corporation to partner in Bulk piezo inkjet printheads, echoing the partnership it signed with Ricoh in March for Thin Film piezo printheads. This is in line with Xaar’s 2020 vision announced in March 2016, extending Xaar’s product offering through collaborative development. The partnership is expected to provide net benefits to both partners through incremental sales and more cost-effective technology development, although we do not anticipate any changes to our forecasts in the near term.
Making Mobiles Better
17 Jan 17
Mobile phones are increasingly the key connection for the modern world. This means that the performance of mobile phones, and their networks, is going to become more critical for all the apps and businesses that rely on them. New technologies such as VR, AR, and AV will need better, more reliable connections to really move into the mainstream. In this thematic piece we attempt to identify some of the most important issues facing mobile phone networks and their users, and start to identify solutions and enablers that will solve these problems and create value by doing so.